Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05168-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Yuqin Zeng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Third Xiangya Hospital, Central South Universi, Changsha, Hunan, 410013, P.R. China. Hauptthemen laut MEDLINE: Drug Eruptions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province.
Themen: Patientensicherheit
Abstract (Originalsprache)
This study aimed to systematically evaluate cutaneous adverse events (AEs) associated with Rybrevant (amivantamab), the first bispecific antibody targeting EGFR and MET, using the FDA Adverse Event Reporting System (FAERS) database. Using data from the FAERS between Q2 2021 and Q4 2024, we conducted a comprehensive evaluation of AEs related to Rybrevant. After data cleaning, 1,372 unique cases were identified where Rybrevant was designated as the primary suspect drug. Among these, 483 cutaneous AEs were included for further analysis. At the Preferred Term (PT) level, paronychia, dermatitis acneiform, and skin toxicity showed the highest signal intensities. Sex disparities revealed folliculitis as more prevalent in males. The median time-to-onset (TTO) of cutaneous AEs was 11 days (range: 0-139 days), with rash occurring earliest (median TTO less than 1 days) and skin toxicity latest (median: 139 days). Besides other events, hospitalization events were the most common clinical outcome of cutaneous AEs. Rybrevant-associated cutaneous AEs are significant and heterogeneous in real-world settings, with paronychia and dermatitis acneiform representing critical risks. Early monitoring and tailored management are essential, particularly for long-term users.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Third Xiangya Hospital, Central South Universi, Changsha, Hunan, 410013, P.R. China.
- XiangYa School of Medicine, Central South University, Changsha, Hunan, China.
- Department of Dermatology, Third Xiangya Hospital, Central South Universi, Changsha, Hunan, 410013, P.R. China. 330431848@qq.com.
- Department of Dermatology, Third Xiangya Hospital, Central South Universi, Changsha, Hunan, 410013, P.R. China. zengqinghai@csu.edu.cn.
Förderung
- Natural Science Foundation of Hunan Province
Zitieren
APA
Zeng, Y., Li, Y., Du, Z., Shu, R., Fu, C., & Zeng, Q. (2026). Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05168-1
Vancouver
Zeng Y, Li Y, Du Z, Shu R, Fu C, Zeng Q. Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05168-1
BibTeX
@article{Zeng2026,
author = {Zeng, Yuqin and Li, Yidan and Du, Ziye and Shu, Risheng and Fu, Chuhan and Zeng, Qinghai},
title = {Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05168-1}
}
EUVIMED